BCG report 2012
The new vfa bio report “Medical Biotechnology in Germany 2012 – Biopharmaceuticals: Economic data and new application areas with benefit for patients” is now available. It was provided by The Boston Consulting Group. This yearly report is the only one recording all activities within medical biotechnology in Germany – ranging from startup to big companies.
read on
Biotech report 2011
Medical Biotechnology in Germany 2011 – Biopharmaceuticals: Economic Data and Benefit of Personalized Medicine
(© BCG)
The new report “Medical Biotechnology in Germany 2011 – Biopharmaceuticals: Economic data and benefit of personalized medicine” is now available. It was provided by The Boston Consulting Group for vfa bio. This yearly report is the only one recording all activities within medical biotechnology in Germany – ranging from startup to big companies.
read on
read on
Biotech Report 2010
Medical Biotechnology in Germany 2010 – Benefit of Biopharmaceuticals for Children
The new report “Medical Biotechnology in Germany 2010 – Benefit of Biopharmaceuticals for Children” is now available. It was provided by The Boston Consulting Group for vfa bio. This yearly report is the only one recording all activities within medical biotechnology in Germany – ranging from startup to big companies.
read on
read on
Medical Biotechnology Holds Steady During Crisis
(© Boehringer Ingelheim)
Medical Biotechnology has weathered the economic crisis well. This was announced at the launch of the Industry Report “Medical Biotechnology 2010”. The report was produced by the Boston Consulting Group. The study provides an overview of the German biopharmaceutical industry, and analyzes the medical biotech activities of small and medium-sized companies, as well as large corporations.
read on
read on
Suggest page
Print page